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CHAPTER 1: GENERAL INTRODUCTION 
Thesis Organization 
This thesis composed of three chapters. Chapter one presents a general introduction and 
review of different diagnostic methods for the detection of porcine reproductive and 
respiratory syndrome virus (PRRSV) or its infection in swine. This general introduction 
provides a broad overview of current knowledge of diagnosis perspective and background for 
research work presented in chapters two. Chapter two describes development of western 
immunoblotting and luminex® technology-based tests with recombinant PRRSV 
nucleocapsid protein prepared by baculovirus expression system and establishment of an 
epitope-based blocking ELISA using the existing commercial ELISA kit (2XR) for PRRSV 
(IDEXX) in comparison to a newer version of the commercial ELISA kit (X3), leading to 
developing A testing algorithm for confirmation of suspect false positives results occurred in 
the commercial ELISA. The final chapter includes general conclusions of the research 
studies and suggests possible direction of future studies. 
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Literature Review: PRRS virus diagnostics and diagnosis 
Introduction 
Historical aspect of PRRS  
Porcine reproductive and respiratory syndrome (PRRS) was first observed in 1987 in the 
United States 42,48 and rapidly spread through North America. The first outbreak in Europe 
was recognized in late 1990 in Germany 55, and then became widely spread throughout the 
European continent. By 1994, PRRS was identified in most of major pig producing areas 
throughout the world 66. 
PRRS was initially named ‘Mystery Swine Disease’ because no known etiologic agent 
could be established to be responsible for the disease (39). In Europe the disease was 
occasionally named “Blue ear pig disease” because of distinctive appearance of gross skin 
lesion (48). The causative virus was first isolated in The Netherlands in 1990 and designated 
as Lelystad virus (LV) 106 and shortly after in the US it was also isolated and named as the 
Swine Infertility and Respiratory Syndrome (SIRS) virus 17. 
Although several names were applied to the disease since its emergence, International 
Office of Epizootics (O.I.E) designated the name ‘porcine reproductive and respiratory 
syndrome’ to the disease and resulted in the causal agent called ‘Porcine Reproductive and 
Respiratory Syndrome Virus (PRRSV).’ 
 
Clinical Manifestations 
In general, a PRRS outbreak is characterized by episodes of respiratory distress as well 
as decreased farrowing rate and elevated mortality due to an increased number of stillborn 
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pigliets 48,96. However, polymorphic clinical presentations are one of the most common 
features of PRRS 108. PRRSV infections in adult animals, particularly boars, can undergo 
unnoticed from a clinical point of view 68,86. For example, only three out of 29 
experimentally infected boars showed transient inappetence and depression for only one or 
two days 84,85. Other research group also reported similar observation in experimentally 
infected boars 14,95. 
The prevalence of PRRS varies depending upon animal age, pig density, health status, air 
quality, and exposure dose of virus 22,86. Yet, the severity of the disease can also be affected 
by the strain of virus. Research done on pigs experimentally infected with nine different 
isolates of PRRSV showed differences in clinical signs, rectal temperatures, gross and 
histological lung lesions and mortality rate 38,39. Furthermore, higher level of viremia and 
higher viral concentration in tissues may be related to the severity of PRRS. Highly virulent 
strains of PRRSV tend to replicate more efficiently in the host to a higher level 43. In addition, 
a whole range of bacterial agents like Streptococcus suis, Salmonella choleraesuis and 
Mycoplasma hyopneumoniae appeared to enhance the severity of clinical manifestations 
following PRRS 27,97,109. 
 
Economic impact of PRRS 
 For the past two decades, PRRS has become one of the most threatening diseases to 
swine health and production globally since it was first reported in the United States in the late 
1980s 48,96. Porcine reproductive and respiratory syndrome is currently considered to be the 
most economically important infectious disease that is faced by swine industry in the United 
States. Estimated annual economic losses due to PRRS in the US swine industry are 
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approximately $560 to $762 million 45,73. The economic burden by PRRS is due to increased 
respiratory disease and pre-weaning mortality, decreased farrowing rates, higher chances for 
secondary infection by other diseases, decreased growth rate, and additional diagnostic, 
therapeutic and vaccine costs. The most significant economic loss due to PRRSV infection is 
generally observed in nursery and finishing phases of production 73.  Compared with other 
historical nightmare of swine producers, the annual cost of PRRS exceeds the costs of 
pseudorabies and classical swine fever 31,40. In order to control and prevent the disease, a 
great deal of efforts has been mounted to develop efficacious vaccines for PRRSV 98. 
Nonetheless, the effective control and eradiation strategy is still based on accurate 
identification of infected animals 4. Therefore, rapid, convenient and reliable laboratory 
confirmatory tests are needed for accurate diagnosis. 
 
Porcine reproductive and respiratory syndrome virus 
Porcine reproductive and respiratory syndrome virus is a small enveloped, 
single-stranded positive-sense RNA virus with approximately 50-65nm in diameter. The 
PRRSV belongs to the family Arteriviridae with equine arteritis virus (EAV), 
lactate-dehydrogenase elevating virus (LDV) and simian hemorrhagic fever virus (SHFV) 
within the order Nidovirales 11,18,82. Members of this family share many biological and 
molecular properties, including virion morphology, genomic organization, and gene 
expression strategies. They also have the ability to: a) induce prolonged viremia; b) establish 
persistent infections; and c) grow in macrophages 82. Overall, PRRSV is more closely related 
to LDV and EAV than SHFV 63. 
Two different major genotypes have been identified among PRRS viruses: the European 
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(type 1) and North American (type 2) types. They share less than 70% sequence homology in 
their entire genome. Comparative sequence analysis revealed certain degrees of amino acid 
identity between Lelystad virus and VR2332, ranging from 55% (ORF5), 79% (ORF6) and 
64% (ORF7) 44,61,70,71,94. 
The viral genome (approximately 15kb in size) encodes at least nine open reading frames 
(ORFs) that express a set of co-3’ end nested subgenomic mRNAs with the same leader 
sequence at the 5’ end 3,20. The ORF1a and ORF1b compose almost 12kb of 5’end of the 
genome and encode nonstructural proteins (Nps) including RNA-dependent-RNA 
polymerases that was required for virus replication 23,62,63. Three N-glycosylated minor 
envelope proteins (GP2, GP3, and GP4) were translated from ORF2, ORF3, and ORF4 
respectively and form a heterotrimer, playing a role in the attachment of PRRSV to target 
cells 110. ORF2b, which is completely embedded in ORF2a, encodes non-glycosylated minor 
envelope protein (2b) 112. The major envelope glycoprotein of 25 kDa (GP5 or E) expressed 
by ORF5 is the main receptor molecule of PRRSV, forms a heterodimmer with 18-19 kDa 
unglycosylated matrix (M) protein that is expressed by ORF6 59. The 15-kDa nucleocapsid 
(N) protein, which is highly immunogenic and antigenically conserved among PRRS viruses, 
is expressed by ORF7 65. 
 
Immunology 
 Previously infected sows neither transmitted virus to their fetuses nor suffered from 
reproductive failure when subsequently challenged with a virulent strain during late gestation 
34,51, indicating that solid protective immunity can be conferred by the prior infection. 
PRRSV-specific immunoglobulin M (IgM) and IgG responses rapidly appear in animals after 
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exposure to the virus 56,102. Detectable antibody against PRRSV can be found in some pigs as 
early as 5-7 days post infection (PI) and by day 14 PI most, if not all, of the infected animals 
seroconvert to the virus 115,120 as determined by indirect fluorescent antibody (IFA) test or 
enzyme-linked immunosorbent assay (ELISA). The ontogeny of antibody response of pigs to 
PRRSV was studied with a North American PRRSV 72. The antibody against the N protein 
was detected earliest, followed by the M protein, and then the GP5.  
Despite of the fact that pigs rapidly mount virus-specific antibody after exposure, this 
rapid reaction does not correspond to the development of neutralizing antibodies (NAs) 116. 
PRRSV is known to induce delayed production of virus-specific NA. In general, NA is not 
detected during the first 4 weeks after infection 57. However, a critical role of NA in 
protection against PRRSV has been demonstrated 77. Virus clearance from tissue and 
circulation of experimentally infected pigs was shown to coincide with the induction of NA 50. 
GP5 is believed to be most important in inducing the protective antibody since most of the 
NAs are generated against GP5 and contains one of the major neutralization epitopes based 
on in vitro assessment 33,72,79,80. In addition, GP4 and M protein were reported to contain 
neutralization epitopes 9,33,64,104,113. Some reports also suggested that viral epitopes capable of 
inducing NAs reside on the GP3 protein 9,47. Therefore, various membrane-associated 
proteins besides GP5 must be taken into consideration to achieve the full capacity of cross 
neutralization between different PRRS viruses 47. 
The non-NAs developed at early stage may have a significant role in the pathogenesis of 
PRRSV. Yoon et al. reported an immunopathological condition known as antibody-dependent 
enhancement (ADE) of PRRSV in which virus-specific antibodies mediate and enhance virus 
infection in Fc receptor-bearing immune cells such as macrophages, resulting in higher 
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viremia for a longer period 118,119. The epitopes that may induce ADE-mediating antibody for 
PRRSV were associated with the GP5 and N proteins 9,118. Although exacerbation of disease 
severity due to ADE of virus infection has not been demonstrated under experimental 
conditions, enhanced severity of PRRS potentially due to ADE has been reported in the field 
91,119. 
 
Diagnostics 
 Diagnosis of PRRS based on clinical signs is unreliable considering that clinical disease 
is often not overt or of limited duration of clinical signs which can be similar to ones by other 
diseases. Furthermore, no pathogonomonic gross lesions specific for PRRSV infections have 
been demonstrated in infected pigs, and the only consistent microscopic lesion is interstitial 
pneumonia 19,83. In addition, secondary or concurrent infection by other pathogens often 
occurs with PRRSV infection, which complicates the recognition of the disease. Therefore, 
laboratory diagnostic testing is necessary to aid accurate diagnosis of PRRS. Various 
laboratory tests have been developed for the detection of specific antibodies and for virus 
since the discovery of PRRSV. 
 
Detection of PRRSV or viral components 
Virus isolation (VI), immunohistochemistry (IHC) and polymerase chain reaction 
(PCR)-based assays are commonly employed to detect PRRSV directly. 
1 Detection of infectious PRRSV – VI 
Virus isolation test is considered as “gold standard” for PRRSV diagnosis. The VI test is 
done using porcine pulmonary alveolar macrophages (PAM), natural host cell, or African 
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monkey kidney cell line or its derivatives 17,46,106. Differences of individual strains in the 
ability to grow in PAM or cell lines have been reported in a previous study 5. For type 1 
PRRSV, PAM have been reported to be most sensitive and in many cases is the only cell 
supporting PRRSV virus growth in vitro. 
 This technique, however, has some drawbacks. As mentioned above, PRRS viruses differ 
in their ability to grow in PAM and the cell lines. Hence, both cells should be utilized for 
better coverage of various PRRS viruses in VI. Use of PAM requires multiple batches since 
different batches may be not equally susceptible to the virus. The PAM need to be harvested 
from pigs under 6 to 8 weeks of age, preferably specific-pathogen-free pigs 114, which is 
cost-prohibited in some laboratories. Many times VI requires more than one passage 105. 
Therefore, all these disadvantages make VI a rather laborious and expensive method which 
may not be suitable for large scale testing.  In addition, longer turnaround time (7-14 days) 
of test result is another downside of using VI as routine diagnostic test when rapid diagnosis 
is critical for disease control. 
2 Detection of viral antigen(s) – IHC 
Detection of PRRS viral antigen(s) in frozen sections of tissues, ethanol-fixed or 
formalin-fixed tissues by using immunoperoxidase or immunogold silver staining (IGSS) has 
been demonstrated as an effective diagnostic tool for PRRSV in nursery and grower/finishing 
pigs 37,58,83. The method has been reported to be highly specific but with only moderately 
sensitivity 38. The results from IGSS on different ethanol-fixed tissues are comparable to 
those of virus isolation 58. However, it should be noted that this method, depending upon test 
type, can be time-consuming and may have a better application for research purpose than 
diagnosis. Besides, the uneven distribution of PRRSV antigen in tissues (particularly lungs) 
  
9
of infected pigs often limits the detection of virus infected animals with this method, 
although other reports have indicated that IHC most consistently identified PRRSV in the 
lung 52,54,87. 
3 Detection of viral genome – PCR 
Assays based on PCR technology have been the focus of recent assay development for 
detecting PRRS viral nucleic acids in clinical specimens. Reverse transcription-polymerase 
chain reaction (RT-PCR) in various formats or platforms have been used to detect the viral 
RNA of PRRSV 15,49,53,54,60,101, 16. In North American veterinary diagnostic laboratories, 
real-time RT-PCR is commonly used and commercial real-time RT-PCR reagents/kits are 
available to the diagnostic community 30,103. 
It has been demonstrated that multiplex RT-PCRs can efficiently differentiate North 
American (type 2) strains from European (type 1) strains of PRRSV by means of specific 
oligonucleotide primers or probes that are designed according to the sequence of the 
nucleocapsid protein (N) gene 60. Restriction fragment length polymorphism (RFLP) analysis 
of PRRSV’s ORF5 which is coupled with PCR amplification of the target gene was devised 
to rapidly differentiate the PRRS vaccine virus from North American field strains of PRRSV 
107. Such a differential utility of the assay has diminished since the vaccine virus was reported 
to spread from vaccinated pigs to non-vaccinated animals causing the disease and continue to 
circulate in a population 74. In addition, RFLP appears not to be able to accurately determine 
the relatedness among PRRS viruses since restriction enzyme sites frequently undergo 
genetic mutation 117. 
PCR technology possesses a great advantage over virus isolation in detection of PRRSV in 
samples with reduced infectivity or cytotoxicity, such as autolyzed tissues, semen or 
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environmental samples 15. In recent years, a number of PCR-based methods including 
one-step RT-PCRs and nested RT-PCRs have been published for the detection of PRRSV in 
tissue and body fluids of infected animals 32,35,49,60,76,92. RT-PCRs for the detection and 
differentiation of PRRS viruses are used as sensitive and highly specific diagnostic tools to 
control PRRS or to monitor the negative status of herds. Although PCR provides promising 
sensitivity and rapid diagnosis, the approach is costly, as it requires specialized laboratory 
equipment and experienced technicians. In addition, increased false positive results were 
reported from herds negative for PRRSV infection 29. 
 
Serological tests 
 In addition to direct methods of agent detection, antibody detection has been commonly 
used for serodiagnosis of PRRSV infection. Serologic tests for PRRSV include the indirect 
fluorescent antibody (IFA) test, serum-virus neutralization (SVN) test, immunoperoxidase 
monolayer assay (IPMA) and enzyme-linked immunosorbent assays (ELISA). Currently, 
commercialized ELISA kit (IDEXX Laboratories, Inc., ME) is most commonly used in North 
American veterinary diagnostic laboratories. 
1 Immunoperoxidase monolayer assay and indirect fluorescent antibody test 
 The IPMA was the first serological test reported for the serodiagnosis of PRRS 106. 
Subsequently, the IFA test, which is equivalent to the IPMA, was developed in the United 
States 115. Both tests were initially developed using PAM cell, but later adapted to cell lines 
such as MA104, CL2621 or MARC-145 5,46,106,120. The IPMA was extensively used in 
European laboratories whereas the IFA test has traditionally been the preferred approach for 
serological screening of pigs for PRRSV infection in the United States. The IPMA and IFA 
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test are thought to be highly specific and sensitive 106,115. Under experimental conditions, 
these tests can detect antibodies to PRRSV between seven to fourteen days after inoculation. 
Peak antibody titers tend to be reached after four to six weeks after infection and then decline 
slowly until approaching the lower detection limit of the assay around six to twelve months 
after initial exposure 1,120. However, these tests need to be done in laboratories with special 
facilities, and test results, particularly endpoint titer, can vary due to subjective reading of test 
result by laboratory personnel. The existence of antigenic variation among PRRS viruses can 
lead to false negative in these tests if the virus used in the assay is antigenically distinct from 
the virus causing disease in a herd or farm. Furthermore, these tests need to use cell culture, 
which is laborious and cannot be automated for large-scale use. 
2 Enzyme-linked immunosorbent assay 
 The advantage of the ELISA compared with IPMA and IFA is that it can be automated 
and performed economically for large-scale examination. Development of an indirect ELISA 
for detection of PRRSV-specific antibodies was first reported at 1992 2, using cell culture 
supernatant of infected alveolar macrophage culture as antigen. This method was reported to 
be more sensitive than IPMA, particularly for early antibodies detection. However, 
unacceptable high background signals were also observed in an in-house ELISA for some 
seronegative sows 26. Since then, several in-house indirect ELISAs have been reported by 
others to eliminate the high background issue 7,12,21,24,25,28,69,81,90,93,111. Nevertheless, 
preparation of antigens and ELISA plates in a testing laboratory was time-consuming and 
required skill and rigid quality assurance to prepare those in a consistent manner with 
consistency and quality. The availability of a commercial ELISA kit (e.g., IDEXX 
HerdCheck PRRS 2XR antibody ELISA) to the diagnostic community has eliminated such 
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difficulties and concerns. 
 Development of a blocking ELISA (bELISA) with antigen derived from infectious 
PRRSV using polyclonal antibodies as the detection system, has been reported 41,93. The test 
was reported to be specific and more sensitive than the IPMA when applied to field sera and 
to sera which were collected early after an experimental infection with PRRSV. High 
background which was observed in IPMA or indirect ELISA was not encountered with 
bELISA. Higher specificity of the assay made it more suitable as confirmatory testing when 
suspect false positive result occurred in other serologic assay including the commercial 
ELISA kit. 
3 Serum-virus neutralization test 
 Virus-specific NAs are produced in animals after infection with PRRSV although 
antibody level varies among virus strains and animals. The antibodies can be measured in an 
SVN test using cell lines 67. The SVN test is also considered to be a specific test, but with 
lower sensitivity as compared to IPMA, IFA or ELISA for detection of antibody early after 
infection 6,13,67. However, the sensitivity of this method could be enhanced by adding fresh 
normal swine serum as source of complement to the serum being assayed 116. This 
modification increased the sensitivity of the test and made it possible to detect neutralization 
titers as early as 11 days post infection. Those early detectable NAs were of IgM isotype 
whose neutralizing activity was dependent upon the presence of complements. The most 
significant drawback of SVN test is that test results can be severely compromised by 
antigenic variability which is known to exist among PRRS viruses 8. Considering its 
laborious nature, SVN test is less suitable for routine diagnostic use even though it is only 
assay measuring functional antibody against PRRSV 
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Diagnosis 
 In the field, suspicion of PRRS in breeding animals and farrowing houses is based on 
clinical signs of reproductive failure (increased mummified fetuses and stillborn piglets) 
particularly at late gestation and a high level of neonatal/pre-weaning mortality 48,96. Boars 
may show loss of appetite and libido. For growing-finishing animals, lethargy and respiratory 
distress (clear nasal secretion, dyspnea) is the main clinical presentation due to PRRS100. 
Therefore, similar respiratory and/or reproductive symptoms should be differentiated from 
PRRS through laboratory testing. PRRSV-induced reproductive disease need to be 
differentiated from leptospirosis, porcine parvovirus infection, and porcine enterovirus 
infection (SEMID), haemagglutinating encephalomyelitis virus infection causing 
Encephalomyelitis, Aujeszky’s disease, African swine fever and classical swine fever. For the 
respiratory and post-weaning form of PRRS, differential diagnosis should include: swine 
influenza, Mycoplasma enzootic pneumonia, proliferative and necrotizing pneumonia 
(caused by porcine circovirus type 2), Haemophilus parasuis infection (caused by 
Haemophilus parasuis), haemagglutinating encephalomyelitis virus infection, porcine 
respiratory coronavirus infection, syncitial pneumonia and myocarditis (caused by respiratory 
syncytial virus), postweaning multisystemic wasting syndrome and Nipah virus infection 75. 
Laboratory investigation consists of pathological examination, virological testing and/or 
serological testing depending upon disease stage. No pathognomic gross lesions specific for 
PRRS have been identified although abnormal changes are present in many internal organs 
(e.g., lung, regional lymph nodes, spleen) of affected animals. For examples, lungs from 
affected pigs are generally swollen, firm, tan-colored, and marble looking. Lymph nodes are 
enlarged 36. Microscopically, type 2 interstitial pneumonia is the most common lesion in 
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lungs of affected pigs along with lymphadenopathy and inflammation in various secondary 
lymphoid tissues 88. 
For virological testing, immunohistochemistry (IHC) and RT-PCR assays are commonly 
used although virus isolation test is considered to be “gold standard”. PRRSV and/or viral 
antigens have been detected in almost all internal organs (lung, spleen, tonsil, lymph nodes, 
thymus, heart, liver, kidney, brain), bone marrow and bodily fluid (serum, saliva, nasal 
secretion, fetal thoracic fluid, semen) 25,88. Nonetheless, serum is often a preferred specimen 
for PRRSV testing because it can be used for both virological and serological tests 99. Serum 
samples are particularly useful for the diagnosis of PRRS when PRRSV is suspected to cause 
reproductive disorder in breeding animals including boars 89. Since PRRSV can easily lose 
infectivity at room temperature or higher, it is important to keep cold chain when fresh tissue 
or bodily fluid samples including serum are submitted to a diagnostic lab particularly for 
virus isolation 75. Care must be also taken when interpreting virus testing results (particularly 
PCR) since PRRSV is known to induce prolong viremia and to persist in animals after 
infection without clinical disease10. It is recommended to do both histopathological 
examination and viral testing along with clinical assessment to get accurate diagnosis of 
PRRS. 
For serology, ELISA is a preferred laboratory method for testing although IFA or SVN 
tests have been used. Yoon et al 120 studied the humoral immune response of pigs to PRRSV 
after experimental infection. Virus-specific antibodies were first detected by the IFA, IPMA, 
ELISA, and the SVN test 9-to-11, 5-to-9, 9-to-13, and 9-to-28 days post inoculation and 
reached their maximum values by 4-to-5, 5-to-6, 4-to-6, and 10-to-11 week’s dpi, 
respectively. It was estimated by regression analysis that the ELISA, IFA, IPMA, and the 
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SVN antibodies would approach the lower limits of detection by approximately day 137, 158, 
324, and 356 dpi, respectively. Colostrum-derived passive antibody is believed to be weaned 
out by 6 to 10 weeks after birth. Since interpretation of serology results can be influenced by 
the presence of antibody incurred by prior infection, antibody of vaccination origin or 
material antibody, paired serology is highly recommended for accurate serodiagnosis. 
Considering that 65-70% of swine in the US can have a serological evidence of PRRSV 
infection, diagnostic value of serology can be enhanced if IgM-based assays are applied. Park 
et al. demonstrated a proof-of-concept using IFA test 78. 
 
Conclusion 
Generally speaking, virological diagnosis is difficult since cell culture or special 
equipment is needed, whereas serological diagnosis is easier to perform with good specificity 
and sensitivity on a herd level. Continuous genetic and antigenic variation among PRRS 
viruses has been identified as a strong impediment to the accuracy of diagnostic testing. 
Different kinetics of antibody persistence in individual animals and uncertainty over 
significance of seropositive results with respect to PRRS status may also be problematic. In 
addition, no serological test can be recognized as “gold standard” due to the fact that the 
sensitivity and specificity of tests can hardly reach to 100%. Therefore, an accurate and cost 
effective diagnostic method still needs to be developed. 
 
Statement of Problem 
Several serologic methods have been established to monitor the PRRS status of swine 
  
16
herds. Among these tests, ELISA has been most commonly accepted by the diagnostic 
community because of its good repeatability, perceived good quality control, specificity, fast 
turnaround time and relatively low cost. A commercial PRRS ELISA kit manufactured by 
IDEXX Laboratories is in worldwide use for its sensitivity, reliability and ability to meet the 
high demand for both population-based testing and individual animal testing. It can detect 
antibody against both European and North American PRRSV simultaneously but not in a 
differential manner. Few, if any, serological tests reach 100% accuracy, and the PRRS ELISA 
is no exception to this rule. The occurrence of false positives in this commercial ELISA kit 
was claimed to be approximately 0.5-0.6% based on estimated specificity; however, field 
experience and research data suggested that a suspect false positive (SFP) rate in the kit can 
range from 0.5% to 15%. Because of our reliance on serology for effective PRRS prevention 
and control, it is necessary to develop assays with improved performance or testing 
algorithms for verifying test results when SFP samples are presented. 
 
Hypothesis, objective and specific aims 
The hypothesis of the project presented here was that the suspect false positive (SFP) 
rate generated by IDEXX PRRS ELISA 2XR kit can be greatly reduced by following up 
alternative assays. The objective of the project was then to develop testing strategies to 
address the SFP issue when it occurs during primary testing with the following specific aims: 
1. Establishing Western immunoblotting and microsphere immunoassay using recombinant 
PRRSV nucleocapsid proteins; 
2. Applying a blocking ELISA format to the commercial ELISA 2XR kit and validate test 
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performance; 
3. Assessing the diagnostic performance of IDEXX PRRS ELISA X3 kit which was 
recently released from IDEXX as new version of PRRS ELISA 2XR kit; and 
4. Evaluating the diagnostic utility of all assays for verifying SFP results. 
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CHAPTER 2: TESTING ALGORITHM FOR CONFIRMATION OF 
SUSPECT FALSE POSITIVES IN A COMMERCIAL ELISA KIT FOR 
PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS 
(PRRSV) 
Siyuan Liu, Won-Il Kim, Sheela Ramamoorthy, John Johnson, Chong Wang, Kyoung-Jin 
Yoon 
Department of Veterinary Diagnostic and Production Animal Medicine 
College of Veterinary Medicine, Iowa State University, Ames, IA 50011 
(to be submitted to Journal of Veterinary Diagnostic Investigation) 
 
Abstract 
The commercial ELISA kit (IDEXX HerdCheck® PRRS) has been the main 
serodiagnostic tool for PRRS virus (PRRSV) in North America and many pig producing 
regions throughout the world. Although the kit has been mostly a reliable test for detecting 
PRRSV exposure at the herd level, the specificity of the kit has been frequently challenged 
by the occurrence of unexpected false positive results at varying rates. An indirect fluorescent 
antibody (IFA) test has been commonly employed to confirm or disprove the suspect false 
positive reactivity in the ELISA. However, the reliability of test results have been often 
questioned due to the subjectivity in determination of test result and perceived lower 
sensitivity. The current study was conducted first to develop immunoassays (Western 
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immunoblot and microsphere immunoassay) based on recombinant N protein of PRRSV as 
well as bELISA using the existing commercial ELISA kit (2XR). Then diagnostic 
performances of four different serologic assays (Western immunoblot, microsphere 
immunoassay, bELISA and new IDEXX’s PRRS ELISA kit X3) was evaluated on the same 
set of experimental and field serum samples in comparison to ELISA 2XR kit to establish a 
confirmatory testing algorithm when suspect false positive (SFP) results occur in ELISA 
2XR. All assays showed excellent performance on experimental samples, meaning that all 
tests are valid for specific and sensitive detection of the target antibody. Diagnostic 
sensitivity and specificity of the assays related to ELISA 2XR, however, varied on the field 
samples, although all of them greatly reduced the number of SFP samples. By combining two 
different assays (particularly ELISA X3 and Western immunoblotting), the SFP results could 
be reduced by as high as 73.5% which provide higher confidence in determining the PRRS 
status of animal when SFP results occur. 
Key words: PRRSV, diagnostic confirmatory test performance, test algorithm 
 
Introduction 
Porcine respiratory and reproductive syndrome virus (PRRS) is caused by an arterivirus 
named PRRS virus (PRRSV) 34 has had a catastrophic economic influence on swine industry 
45 since its emergence on three continents in the last two decades 2,3,11,28. The disease was first 
observed in 1987 in the US and in 1990 in Europe 27 and is characterized by manifestation of 
late term abortion and stillbirths in sows and respiratory disease in pigs of all ages 29,40. Since 
its appearance, two major genotypes have been identified, European (type 1) and North 
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American (type 2) 5,24,26,40, which develop similar clinical symptoms but shares only 50% 
nucleotide sequence homology 6. Nowadays, both genotypes can be found in the United 
States and Europe 9,31. 
PRRSV is an enveloped virus containing single-stranded positive-sense RNA genome of 
approximately 15Kb in length which encodes nine open reading frames (ORFs) 6,39,42. ORFs 
1a and 1b compose approximately 80% of the 5’ end of genome and encode RNA replicase 
complex. ORFs 2a, 3 and 4 encode for minor envelope glycoproteins (GP2, GP3, GP4) of 
PRRSV 21. ORF2b encodes a minor nonglycosylated protein (2b) associated with viral 
membrane 42. The major structural proteins glycoprotein 5 (GP5 or E), nonglycosylated 
matrix (M) protein, and nucleocapsid (N) are encoded by ORF5, ORF6 and ORF7 
respectively 21. 
Among viral proteins, the N protein is expressed abundantly in infected cells and 
constitutes about 20-40% of the virion protein 1,18,26. The N protein is highly basic and  15 
kDa in size 19,21. The N protein can multimerize to form icosahedral core structures around 
genomic RNA 18,21. Most anti-PRRSV immunoglobulins in serum of infected animals are 
directed against the N protein 6. Antibody against N protein can be detected within 7 days of 
infection 17,25,44. The N proteins of European and North American PRRSV strains have both 
conserved and divergent epitopes that can be recognized by monoclonal antibodies 23. 
Because of the advantages described above the N protein has been applied to several 
diagnostic tests as the target antigen 7,8,10,33,41. 
Porcine reproductive and respiratory syndrome costs the US swine industry 
approximately $600 million annually 13 due to respiratory disease, increased mortality in 
piglets and reproductive disorder, weight loss and poor performance in grow-finishing pigs 
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16,37. In most of the cases, infected animals can undergo without overt clinical signs, which 
makes the accurate clinical diagnosis more difficult to perform 22,30. Therefore, accurate and 
timely laboratory diagnosis of virus infection is necessary for effectively monitoring 
infection status and controlling the disease. Serology has been a useful tool to determine 
PRRS status of herds or individual animals and to monitor the PRRSV infection or 
vaccination. Several serological assays have been developed for PRRSV, such as indirect 
fluorescent antibody (IFA) test, serum-virus neutralization (SVN) test, immunoperoxidase 
monolayer assay (IPMA) and enzyme-linked immunosorbent assays (ELISA). Among those 
tests, the ELISA has been preferred because of its high sensitivity, relatively low cost, fast 
turnaround time and high throughput. 
The commercial indirect ELISA kit (HerdCheck®) manufactured by IDEXX 
Laboratories is in use worldwide for its good sensitivity and specificity and built-in quality 
control. Additional advantage of IDEXX ELISA kit is that it can reliably detect antibodies to 
both genotypes of PRRSV. Even with many advantages, it has been observed that the IDEXX 
ELISA produced unexpected positive results in seronegative herds where the farm and herd 
history lead to the strong expectation of negative results 10,32. The rate of unexpected false 
positive results (i.e., singleton reactors) has been as high as 5% or sometimes reached 15% at 
herd level based on data in a veterinary diagnostic laboratory (K-J Yoon, unpublished data). 
This is much higher than expected based on the specificity (99% or higher) claimed by the 
manufacturer. The occurrence of singleton reactors in the commercial ELISA kit have had 
significant impact on effective control of PRRS, which is based on an accurate identification 
of infected animals or accurate assessment of PRRS status in herd. 
When false positive results are suspected, polymerase chain reaction (PCR) based assay, 
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virus isolation (VI), and/or indirect fluorescent antibody (IFA) tests have been commonly 
employed as follow-up methods to resolve the question of the unexpected positive samples. 
Although PCR and VI can detect viremic pigs within 24 hours post exposure, both methods 
have several drawbacks. The VI test has a long turnaround time of results. Not all PRRS 
viruses replicate equally well in vitro. The success of VI from serum decreases as time after 
infection goes on 4. PCR test is a sensitive assay to detect the virus in various sample 
matrices. It can provide fast turnaround of result as compared to VI. However, due to the 
great sensitivity of the assay, false positive results could be a problem for PCR. False 
negative results can also occur in PCR due to continuous genetic mutation of PRRSV 38. 
Both PCR and VI results can lack a correlation with the ELISA results due to timing of 
sampling (viremia versus antibody response) 10, not to mention that VI and PCR cost more 
than ELISA.  
IFA test has been frequently used by many veterinary diagnostic laboratories as a 
confirmatory test when false positive results are suspected in the IDEXX ELISA. The IFA 
assay has shown the antibody detection kinetics similar to ELISA 15,44. Limitations exist in 
IFA assay as well. Cell culture techniques are required to prepare antigens for assay, which 
can prolong turnaround time and may not be feasible to all labs. The PRRSV isolates used in 
the assay may be antigenically different from the virus strain causing the disease in the index 
herds, leading to false-negative results 43. Besides, the subjectivity of reading the assay result 
can result in misinterpretation. Undesirable results can also be caused by nonspecific 
background staining. 
Considering all drawbacks and limitations among the current diagnostic tests available 
for PRRSV, alternative serologic assays with better performance and reliability with potential 
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for automation and/or high throughput was desired. At the same time a testing algorithm for 
confirmation was needed when suspect false positive (SFP) results occurred. The following 
study was conducted to address these needs. 
 
Material and Methods 
Study Design 
Four different binding assays were employed and evaluated on the same set of 
experimental and field serum samples in order to establish a confirmatory testing algorithm 
when SFP results occur in the current commercial PRRS ELISA kit (2XR). The assays 
employed were western immunoblotting assay (WIB), microsphere immunoassay (MIA), 
blocking ELISA (bELISA) and new IDEXX PRRS ELISA kit (X3) which had recently 
released to European market. WIB, MIA and bELISA were selected since these are known to 
have high specificity with sensitivity equivalent to indirect ELISA. The ELISA X3 was 
employed because the manufacturer claimed that the X3 kit has much higher specificity than 
the 2XR kit while it maintains the same sensitivity as the 2XR kit (IDEXX press release). All 
assays were virtually based on the nucleocapsid protein of PRRSV. WIB and MIA were 
developed using recombinant baculovirus-expressed nucleocapsid protein of PRRSV. The 
bELISA utilized the ELISA 2XR kit. For test validation, a total of 131 sera (27 known 
negative and 104 known positive) collected from experimental pigs with known PRRSV 
infection status were used. In addition, a total of 188 swine sera were collected from 
submissions to the Iowa State University Veterinary Diagnostic Laboratory (ISU-VDL) in 
2009 and used to evaluated diagnostic performance of the selected tests in comparison to the 
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ELISA 2XR. Based on results of ELISA 2XR and IFA (and PCR if necessary) and historical 
PRRS monitoring data of farms, the field samples were categorized into 4 groups. Group 1 
was composed of 44 samples that were positive by both ELISA and IFA and other herds or 
sites from the same farm were also tested positive for PRRSV. Group 2 had 68 SFP samples 
that were positive by ELISA with S/P ratio ≥0.4 but negative by IFA and PCR. These samples 
were submitted from farms expected to be PRRS negative based on historical monitoring 
data. Group 3 were consisted of 31 inconclusive (potentially false negative) samples with 
ELISA S/P ratios equal to greater than 0.2 but less than 0.4. Pigs in this category have been 
often considered to be positive by the swine industry and diagnostic community when 
samples were collected from historically PRRS negative or naïve herds. All these samples 
were tested negative by IFA. Group 4 were 45 true negative samples that were negative by 
ELISA with S/P ratio <0.2 and also tested negative by IFA (Appendix). Test results were 
compared to each other and statistically analyzed for the equivalency of performance among 
4 diagnostic tests. 
 
Cells and Viruses 
The type 2 prototype PRRSV strain VR2332 and type 1 prototype PRRSV strain 
Lelystad virus were used as source of the ORF7 gene. Both strains were propagated in 
MARC-145 cells which is a highly permissive clone of African Monkey Kidney cell line 
MA104 14 with Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine 
serum (FBS; Invitrogen, Carlsbad, CA).  
The Bac-to Bac baculovirus expression system was purchased from a commercial vendor 
(Invitrogen Inc.), as well as Spodoptera frugiperda (Sf9) insect cell line which was used as 
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the host for baculovirus transfer vector. Monolayer cultures of Sf9 cells and those infected 
with the recombinant baculovirus viruses were maintained in adherent and suspension culture 
with Sf-900 II serum free medium (GIBCO, Carlsbad, CA). 
 
Biological samples 
Three different independent sets of serum samples were used for the study. First, 32 sera 
with known PRRS status were obtained from an animal study conducted in our laboratory. 
These sera were collected from 16 inoculated pigs and 16 shame control pigs after 65 days 
post inoculation (dpi). All pigs were from a PRRS naïve herd and at 4 weeks of age at the 
time of virus inoculation. 
Second, a total of 88 PRRSV antibody-positive serum samples were obtained through 
sequential bleedings from a previous animal study in our laboratory 36. The samples 
represented 11 pigs randomly selected from a total of 112 pigs used in that study. The 11 pigs 
were inoculated with a type 2 PRRSV (VR2332, JA142 or chimeric virus) at day 0 and 
challenged with VR2332 or JA142 at 44 dpi. Serum samples were collected weekly over a 
72-day period. Sera (n=11) collected at 0 dpi served as negative control sera. All of these sera 
were tested by IFA and serum-virus neutralization (SVN) tests for presence or absence of 
antibody specific for PRRSV.  
Third, 188 field swine sera samples were selected from submissions to the ISU-VDL 
which had more than 10 serum samples. The samples represented various age groups. No 
more than 2 serum samples were selected from the same case submission or same farm/herd. 
All samples were tested by ELISA 2XR and, if necessary, IFA as part of routine serology 
diagnostic service. PCR was also performed on some of these samples when desired to 
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address SFP concern as per clients. Based on test results and historical PRRS monitoring data 
of index herds, 44 positive, 76 negative and 68 SFP sera were identified. The 76 negative 
sera were further divided into 2 categories based on ELISA S/P ratio: a) inconclusive (n=31; 
0.2 ≤ S/P < 0.4) and b) true negative (n=45; S/P<0.2).  
 
Production of recombinant nucleocapsid protein of PRRSV 
Construction of recombinant baculovirus  
To construct baculovirus expression vectors containing ORF7 gene and 6Xhistidine tag, 
the specific cDNA of type 2 and type 1 PRRSV ORF7 was first amplified from the genomic 
RNA of VR2332 and Lelystad Virus, respectively, by Reverse transcription- PCR (RT-PCR). 
Amplification primers contained EcoRI and XbaI sites at the upstream and downstream of 
ORF7, respectively for further manipulation of PCR products. The sequences of the PCR 
primers were as follows: 
NAEcoF 5’-GAATTCGAATTCCAAATATGCCAAATAACAACG-3’ 
NAXbaR 5’-TCTAGATCTAGAAACACTGAGATGCCTCAAGAA-3’ 
EUEcoF 5’-GAATTCGAATTCATGGCCGGTAAAAACCAGAG-3’ 
EUXbaR 5’-TCTAGATCTAGATTAACTTGCACCCTGACTGG-3’ 
Each PCR product and the baculovirus protein expression plasmid vector pFastBac HT 
(Invitrogen) were digested by EcoRI and XbaI (New England BioLabs, Beverly, MA, USA), 
purified after being electrophoresed, and ligated to each other by utilizing the restriction 
enzyme sites. After transformation and selection, pORF7NA, and pORF7EU were obtained, 
in which VR2332 and LV ORF7 cDNA were confirmed by sequencing in the correct 
orientation with respect to the polyhedron promoter. The recombinant pFastBac HT donor 
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plasmid, containing ORF7 gene, was then transformed into competent DH10Bac™ E. coli 
cells for transposition into the bacmid according to the manufacturer’s instructions 
(“BAC-TO-BAC™” manual, Invitrogen). Correct bacmid construction was confirmed by 
nested PCR using M13 and ORF7 gene specific primers as well as sequencing. 
Transfection of Sf9 cells with recombinant bacmid DNA 
Sf9 insect cells (Invitrogen) were transfected with bacmid DNA bac-6×His-ORF7EU or 
bac-6×His-ORF7NA and incubated at 30°C for 72h or until start to see signs of cytopathic 
effect. Rescued recombinant baculoviruses bac-6×His-ORF7EU and bac-6×His-ORF7NA in 
the supernatant were harvested and confirmed by sequencing as P1 viral stock and then used 
to infect fresh insect cells to amplify baculoviral stock until P3 which generated a suitable 
titer (e.g. 1×108 pfu/ml). Cells infected with such viruses were then used as crude antigen for 
western immunoblotting to confirm the presence of each recombinant protein of 17.5 kDa 
and 17.3 kDa in size, respectively. Uninfected cells and the cells infected with wild type 
baculovirus were used as controls for assay. 
Antigen purification 
 The expressed bac-6×His-ORF7EU and bac-6×His-ORF7NA recombinant proteins are 
tagged with 6×His. ProBondTM purification system (Invitrogen) was used to purify the 
recombinant fusion proteins under denaturing condition following manufacturer’s 
recommended procedure. 
 
SDS-PAGE and Western immunoblotting 
Sample preparation 
Sf9 cells infected with baculovirus-expressed recombinant N protein of PRRSV or wild 
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baculovirus (virus control) and uninfected cells (mock control) were pelleted by 
centrigufation for 10 min at 2000 × g. Each of the resulting cell pellets was lysed by three 
cycle of freeze-and-thaw and mixed with 5X sample buffer containing 0.6M Tris-HCl 
(pH6.8), 25% glycerol, 2% SDS, 10% β-mercaptoethanol and 0.1% bromophenol blue, and 
boiled at 100°C for 5 minutes. Samples were cooling down by running water for 30 sec and 
centrifuge for 1 min at 10000 x g. 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Twenty five microliters of each sample were loaded on each well of a 12% 
polyacrylamide precast gel (Bio-Rad Laboratories., Hercules, CA) and electrophoresed for 
90 min at a constant voltage of 100 along with prestained molecular weight markers 
(Bio-Rad). After electrophoresis, recombinant proteins and the markers separated on each gel 
were electrotransferred in transfer buffer (Bio-Rad) onto a 0.45µm nitrocellulose membrane 
(Bio-Rad) for 1 h at a constant voltage of 100 with ice pack. After transfer, membranes were 
blocked with 2% skim milk (Nestlé S.A., Vevey, Switzerland) solution diluted with PBST by 
immerging and gently rocking for 30 minutes at ambient temperature. 
Western immunoblotting (WIB) 
Each serum sample was diluted 1:40 in 20mM Tris-buffered saline solution (pH7.5) with 
0.05% Tween 20 (TBST) and incubated with the membrane contains polypeptides and 
markers for 1 hour at ambient temperature with slow and gentle rocking, and then rinsed 
three times for 5 minutes each using TBST. The membrane was then incubated with 
optimally diluted goat-anti-swine IgG labeled with horseradish peroxidase (Kirkegaard-Perry 
Laboratories, Gaithersburg, MD, USA) for 1 h at ambient temperature with slow and gentle 
rocking. The membrane was rinsed three times for five minutes each using TBST. Then, 
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antigen-antibody reactions were visualized by adding 3,3', 5,5"-tetramethylbenzidine (TMB) 
substrate (Kirkegaard-Perry Laboratories) to the membrane and incubating for up to 5 
minutes at ambient temperature. Distilled water was added to stop colorimetric reaction. The 
presence of antibodies specific for PRRS viral protein in each serum was confirmed by 
existence of specific band with molecular weight as 17.5kDa and 17.3kDa respectively for 
bac-6×His-ORF7EU and bac-6×His-ORF7NA recombinant proteins. 
 
Indirect fluorescent antibody (IFA) Test 
MARC-145 cells were prepared in 96-well plates (Corning Inc., Lowell, MA) and 
incubated at 37°C with supply of 5% CO2 in a humid environment for 48-60 hours. Cell 
monolayers were infected with 100 µl of PRRSV (JA142) at a rate of 104 TCID50/ml for each 
well. After incubation for 20 hours, cells were rinsed three times by 1× phosphate-buffered 
saline (PBS, pH 7.4) and fixed by cold 80% acetone aqueous solution. Uninfected cell 
monolayers were prepared in the same manner and used as cell control antigens. All the 
plates were dried and stored at -20°C until use. Before testing, plates were brought to 
ambient temperature and each well was washed three times with 300 µl of PBS containing 
0.1% Tween 20 (PBS-T). One hundred µl of each serum sample (1:20 diluted) were added to 
duplicate wells, after incubation for 30 minutes at 37°C, serum samples were removed from 
each plate and each well was washed three times by submerging in PBS-T and standing for 5 
min at ambient temperature. Fluorescein isothiocyanate (FITC) -conjugated goat anti-swine 
antibody (KPL) diluted 1:100 in PBS was then added to each well and incubated for 30 
minutes at 37°C. After washing three times with PBS-T, plates were observed under a 
fluorescence microscope. Samples were considered positive for PRRSV antibody in which 
  
30
specific cytoplasmic fluorescence with some intranuclear staining can be observed.   
 
Serum-virus neutralization (SVN) test 
Sera were heat-inactivated for 45 minutes at 56°C prior to being tested. Two-fold serial 
dilutions was made with each serum in RPMI-1640 (Sigma, St. Louis, MO) supplemented 
with 10% FCS (Sigma), 20mM L-glutamine (Sigma), and an antibiotic-antimycotic mixture 
(Sigma) which contained 100 IU/ml penicillin, 100µg/ml streptomycin, 50µg/ml gentamicin 
and 0.25mg/ml amphotericin B (hereafter, RPMI growth medium). Each diluted serum 
sample was then mixed with an equal volume of PRRSV VR2332 at a rate of 103 TCID50/ml. 
After incubating at 37°C for 1 h, serum-virus mixtures were then transferred onto 
MARC-145 cell monolayers prepared in 96-well plates and incubated for another 1 h at 37°C. 
Then all inoculums were removed and cell monolayers were replenished with 200 µl of fresh 
RPMI growth medium. Cells were incubated at 37°C for up to 5 days and monitored daily for 
cytopathic effect (CPE). The presence of virus-specific CPE in each well was recorded. The 
presence of virus in wells without visible CPE was further determined by an 
immunofluorescence microscopy using monoclonal antibody SDOW17 conjugated with 
FITC (Rural Technologies, Brookings, SD). Neutralizing antibody titer of each serum was 
determined as the reciprocal of the highest dilution in which no evidence of virus growth was 
detected. 
 
 
Microsphere immunoassay (MIA) 
Coupling of recombinant PRRSV nucleocapsid antigen to carboxylated microspheres 
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Microspheres (1.25×106) with a carboxylated surface were coated with recombinant N 
protein using two-step carbodiimide procedure as recommended by Luminex Corporation 
(Austin, TX). In brief, selected COOH beads for the protein coupling reaction were activated 
by first mixing with 10 µl of freshly made 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
hydrochloride (Pierce Biotechnology, Rockford, IL) at a concentration of 50 mg/ml followed 
by adding 10 µl of freshly prepared N-hydroxysulfosuccinimide (sodium salt) solution 
(Pierce Biotechnology, Rockford, IL) at a concentration of 50 mg/ml and then agitating the 
beads while being protected from direct light on a rotator at ambient temperature for 20 
minutes. The beads were then washed twice in 150 µl 1× PBS (pH 7.4) and pelleted by 
centrifugation at 14,000 × g for 4 min. The activated beads were resuspended in 100 µl of 
PBS and sonicated (Bransonic, Danbury, CT) for 15 sec. 12 µg of protein sample was added 
to the activated beads, and the final volume was adjusted to 500µl with PBS. Cover the 
microcentrifuge tube with aluminum foil and the beads were agitated with a rotator at 
ambient room for 2 h. The coupled microspheres were then washed with 500 µl wash buffer 
provided in the Bio-PlexTM amine coupling kit (Bio-Rad Laboratories, Hercules, CA), 
centrifuged down, resuspended with 250 µl blocking buffer which was included in kit, and 
then rotated at ambient temperature for 30 min while being protected from light. After 
washing once with 500 µl storage buffer in kit and centrifuge at 16,000 x g for 6 min, the 
resulting coupled bead pellet was stored in 150 µl of the storage buffer in 4°C. The 
concentrations of coupled microspheres in each batch were determined by counting on a 
hemocytometer so that equivalent quantities of each bead set could be applied into the assay. 
Microsphere immunoassay 
To perform a two-step suspension MIA, multiscreen 96-well filter plates (Millipore, 
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Bedford, MA) and a multiscreen vacuum manifold (Millipore, Bedford, MA) were employed 
to facilitate microsphere washing. Briefly, filter plate was blocked with 100µl PBN buffer 
consisted of 1× PBS (pH 7.4), 1% BSA (Sigma) and 0.05% NaAzide (Sigma) for 2 minutes 
at what temperature. Plate was washed once with 190 µl PBS with 0.05% Tween20 (PBST), 
and keep wells moist by adding 20 µl of PBN buffer. Fifty µl of each serum sample which 
was diluted 1:100 in PBN buffer were added to test wells and approximately 2500 antigen 
coated beads in a 50 µl volume of PBN buffer were also added, making final sample dilution 
1:200. The filter plate was sealed with aluminum foil covers and allowed to be incubated on a 
shaker (VWR LabShop., Batavia, IL) at 37°C for 30 minutes and then washed three times 
with PBST by using the vacuum manifold. Optimally diluted affinity-purified biotin-labeled 
anti-swine IgG (1:2500 dilution in 50 µl of PBN buffer) was added to each well. After 
incubation in dark with shaking for 30 minutes at 37°C, plates were washed three times with 
PBST by using the vacuum manifold. After adding steptavidin conjugate (1:100 dilution in 
50 µl of PBN) to each well, incubate the plate in the dark on a shaker at 37°C for 30 minutes. 
After washing twice with PBST by using the vacuum manifold, microspheres were then 
resuspended in 125 µl of PBN buffer per well. Seventy five µl aliquot of each suspension 
was transferred to a clear polystyrene 96-well plate (Costar, Corning, NY) and evaluated for 
the microsphere fluorescence intensity with a LuminexTM 100 instrument (Luminex Corp., 
Austin, TX). The instrument was calibrated with CL1 and CL2 calibration microspheres 
(Bio-Rad Laboratories,) by following manufacturer’s directions. The median fluorescence 
intensity (MFI) of fluorochrome-conjugated secondary antibody bound to individual 
microsphere was derived from a flow analysis of 100 microspheres per well for each sample. 
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Enzyme-linked immunosorbent assay (ELISA) 
Two IDEXX PRRS ELISA kits (HerdChek® PRRS 2XR and HerdCheck® PRRS X3, 
Westbrook, ME) were employed and used as directed by the manufacturer. Samples with 
sample-to-positive (S/P) ratios ≥0.4 were considered positive for antibody against PRRSV. 
The HerdCheck® PRRS X3 is a new PRRS antibody test kit from IDEXX which was 
made available to the European market in mid 2009. The kit was purchased from the vendor 
with United States Department of Agriculture’s permission for import. The manufacturer 
claimed that the specificity and sensitivity of the kit was 99.9% and 98.8% respectively with 
the reduction of false-positive singleton reactors by 90%. 
 
Epitope-based blocking ELISA (bELISA) 
The blocking ELISA was conducted by utilizing PRRS ELISA 2XR kit and following 
the manufacturer’s recommended procedure with a few modifications. Anti-PRRSV 
monoclonal antibody (MAb) SR30 (Rural Technologies Inc., Brookings, SD) which can 
recognize both type 1 and type 2 PRRS viruses was used as detecting antibody after its 
optimal concentration for the assay was determined via a checker board titration. All 
components (diluents, washing buffer, stop solution) provided in the ELISA 2XR kit except 
the secondary antibody were used for the blocking ELISA. Virtually the ELISA was done by 
following the manufacturer’s recommended procedure for ELISA 2XR with a few 
modifications. 
For testing, the plates were incubated with 100 µl each of 1:40 diluted test serum 
samples for 30 min at ambient temperature. For each sample additional set of viral and cell 
control antigen wells was assigned and left without incubating with the sample. Each well 
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was washed with approximately 300 µl of 1X wash buffer three times. 100 µl of optimally 
diluted SR30 MAb (Rural Technologies Inc., Brookings, SD) was added to all wells and 
incubate for 1 h at room temperature. After washing 3 times with wash buffer, 100 µl of 
optimally diluted peroxidase-labeled goat anti-mouse IgG (H+L) (KPL) was added, and 
plates were incubated further for 1h at ambient temperature. The plates were rinsed with 1X 
wash buffer three times and the substrate was added for 15 minutes. Color development was 
stopped by the addition of 100 µl of stop solution. Optical density (OD) of each well was 
measured at 650 nm wavelength in a microplate reader (BioTek, Winooski, VT). The 
blocking index (BI), which is the degree of test serum sample blocking the binding of the 
detecting antibody (i.e., SR30) to PRRSV antigen in well, was calculated using the following 
formula: 
BI=1- (adjusted OD with serum) ÷ (adjusted OD without serum) 
where adjusted OD is the net difference in OD between PRRS well and NHC well (i.e., OD 
of PRRS well - OD of NHC well). 
 
Data analyses 
JMP software (SAS Institute Inc., Cary, NC, USA) was used for receiver operation 
characteristic (ROC) curve analysis on results from experimental serum samples with known 
PRRS status in order to determine the cutoff of each assay.  
For evaluation of clinical serum samples, the diagnostic sensitivity of each assay was 
calculated as the ratio of the number of clinical samples that tested positive to the total 
number of samples that positively identified by IDEXX ELISA 2XR and IFA test. The 
diagnostic specificity of the assay was calculated as the ratio of the number of samples that 
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tested negative to the total number of negative samples.  
Cochran’s Q test (InStat version 2.04; GraphPad Software, San Diego, CA) was used for 
group comparison to assess the equivalency of performance among 4 diagnostic tests 
employed for the study (MIA, WIB, ELISA X3, bELISA) in comparison to the ELISA 2XR. 
Cochran's Q test provides a method for testing differences between three or more matched 
sets of frequencies or proportions. The Cochran test statistic Q was calculated as formulation 
below:  

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where c is the total number of treatments, r is the total number of samples, Cj is the outcome 
totals for jth treatment, Ri is the outcome totals for ith sample, and N is the total outcomes for 
all the samples for all the treatment. The analysis was conducted using the following 
hypothesis: 
Among the four groups (i.e., true positive, suspect false positive, inconclusive (0.2≤S/P<0.4), 
and true negative (S/P<0.2)), 
H0: The four treatments are equally effective 
H1: At least two of the four treatments differ in effectiveness. 
McNemar’s test (InStat version 2.04; GraphPad Software, San Diego, CA) (pairwise 
homogenous comparison) was applied to each pair of the employed assays ( MIA, WIB, 
ELISA X3, and bELISA) for assessing if any two treatments were equally effective. The 
McNemar test is a non-parametric method used on nominal data to determine whether the 
row and column marginal frequencies are equal using the following formula: 
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where b and c denote the discordants between two treatments.  
The hypotheses were: 
H0: The two treatments are equally effective 
H1: The two treatments differ in effectiveness 
 
Results 
Analysis of recombinant bacmid 
Traditional restriction endonuclease digestion analysis was difficult to perform with 
recombinant bacmid DNA due to its large size, which was greater than 135kb. Therefore, 
nested PCR analysis was used to verify the presence of PRRV ORF7 in correct position as it 
was unlikely that any of the unwanted PCR products contained binding sites for both M13 
and PRRSV ORF7 specific primers. Each PCR yielded products with expected molecular 
size. Figure 1A and 1B show PCR products of recombinant bacmid transposed with type 1 or 
type 2 PRRSV ORF7 (2.7kb) from the first run with the M13 primers and type 1 or 2 PRRSV 
ORF7 (400bp) from the second run (nested PCR) with the PRRSV ORF7 specific primers, 
respectively, indicating that the recombinant bacmid containing the PRRSV ORF7 gene were 
constructed successfully. 
 
Expression and analysis of recombinant PRRSV N protein 
The expressed recombinant proteins of bac-6×His-ORF7EU and bac-6×His-ORF7NA 
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were found in the insoluble form. The target protein of type 1 and 2 PRRSV ORF7 with a 
molecular weight of 17.5 kDa and 17.3 kDa, respectively, were immunoprecipitated by 
porcine anti-PRRSV serum sample from lysates of Sf9 cells infected with bac-6×His 
-ORF7EU and bac-6×His -ORF7NA bacmid DNA as shown in Figure 2. The purified target 
recombinant protein of each genotype could be obtained using a metal–chelating resin under 
denaturing conditions, which was still specifically recognized by the PRRSV antiserum 
(Figure 3). 
The antigenic properties of the recombinant N protein expressed by bac-ORF7 were 
further investigated in WIB with a panel of anti-N monoclonal antibodies (MAbs). The 
expressed recombinant protein of type 1 PRRSV ORF7 was recognized only by MAbs 
SDOW17 and SR30 (Fig. 4A) whereas the expressed recombinant protein of type 2 PRRSV 
ORF7 was reactive with all of the MAbs (Fig. 4B). In an immunofluorescence microscopy, 
MAbs SDOW17 and SR30 stained positively with cells infected with bac-6×His -ORF7EU 
or bac-6×His -ORF7NA as these MAbs were expected to recognize N protein of both 
genotypes of PRRSV. On the other hand, MAbs EP147, VO17 and JP28, which specifically 
recognize N protein of type 2 PRRSV isolates 26, did not react with cells infected with 
bac-6×His-ORF7EU (Fig. 4). 
 
Development of recombinant PRRSV N protein-based Western immunoblotting assay 
Two expressed recombinant proteins (bac-6×His-ORF7EU and bac-6×His-ORF7NA) 
were used to set up WIB assay. Total protein concentration of recombinant antigen 
bac-6×His-ORF7EU and bac-6×His-ORF7NA was 8.67 mg/ml and 7.96 mg/ml, respectively. 
Serial 10-fold dilutions from the original antigens were made to determine the optimal 
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working concentration. According to the signal recognition of antigens, 10-2 dilution from the 
original bac-6×His -ORF7EU antigen was chosen for WIB while the 10-1 dilution for the 
bac-6×His -ORF7NA antigens was chosen for the assay. At the given dilution, each antigen 
preparation had total protein concentration of approximately 0.8 mg/ml 
When each of the optimally diluted antigens was tested against polyclonal porcine 
antisera to the VR2332 (type 2) and Lelystad virus (type 1) strains after being serially diluted 
in 2-fold from 1:20 to 1:2560, the antigen bac-6×His-ORF7NA showed the positive result 
with both type 1 and 2 PRRSV antibodies with the endpoint of 1:80 and 1:160 respectively. 
The antigen bac-6×His-ORF7EU had the same results as the bac-6×His-ORF7NA, 
suggesting that both recombinant ORF7 proteins have the same cross reactivity and either 
one can be used to detect antibody against both type 1 and type 2 PRRSV.  
When 32 experimental serum samples from animal study were tested on WIB using the 
recombinant N protein, the test results were highly in accordance with the expected status of 
samples (i.e., no false positive and no false negative). 
 
 
Establishment of the recombinant N protein-based MIA 
A set of microsphere beads was selected to establish the assays to detect antibodies 
specific for PRRSV. When the 32 known positive and negative swine sera were tested on 
MIA in order to establish the cutoff for the assay, clear separation between positives and 
negatives was made by the assay (Fig. 5). The medium fluorescence intensity (MFI) value for 
positive and negative sera was 27349 and 1042, respectively. The cutoff of MFI value was set 
at 4436 as determined by ROC analysis. Results from repeated runs on the same set of the 
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samples demonstrated inter-operator reproducibility of the assay. 
 
Validation and optimization of bELISA 
Based on the checkerboard titration, the optimal concentration of MAb SR30 and serum 
samples dilution was set at 1 μg/ml and 1:40, respectively, which provided the highest BI 
between known positive and negative control sera with minimal background. The cut-off 
value was BI of 0.138 as determined by ROC analysis on 32 experimental serum samples 
with known PRRS status from an animal challenge study. 
 
Comparison of test performance over time 
Swine sera samples collected weekly from 11 pigs at 9 different dpi were tested by 
ELISA 2XR, WIB, MIA, bELISA, and ELISA X3. All of the tests performed on these 
samples similarly with respect to detecting PRRSV-specific antibody (Fig. 6). While all day 0 
samples were negative for PRRSV antibody by all assays evaluated, seroconversion to 
PRRSV was detected in all pigs by all the assays as early as 14 dpi. Antibody reactive to the 
recombinant N protein remained detectable by the last sampling day (i.e., 72 dpi) in 
experimentally infected populations. Interestingly, MIA demonstrated seroconversion to the 
recombinant PRRSV N protein as early as 7 dpi. A total of 2 serum samples which were 
collected from 2 different pigs at two different days were negative on WIB after 14 dpi. 
 
Diagnostic performance of assays in relation to ELISA 2XR 
A total of 120 selected field samples, which consisted of 44 positive and 76 negative 
samples as determined by ELISA 2XR and IFA, were tested by the MIA, WIB, ELISA X3 
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and bELISA. All assays yielded varying numbers of false positive results. False negative 
results were also observed in all the assays except the ELISA X3 kit. In comparison to 
ELISA 2XR, MIA displayed the diagnostic sensitivity and diagnostic specificity of 95% and 
92.4%, respectively, when using the cutoff of MFI 4464. The same diagnostic sensitivity 
(95%) and specificity (92.4%) were observed for bELISA with the cutoff at 0.138BI. The 
diagnostic sensitivity and specificity of WIB was estimated to be 96.7% and 97.8% 
respectively. ELISA X3 showed the diagnostic sensitivity and specificity of 100% and 84.8%, 
respectively. 
WIB had the highest test agreement (97.4%) with ELISA 2XR, while ELISA X3 gave 
the lowest test agreement (90.8%) with ELISA 2XR. Results of MIA and bELISA showed 
93.4% agreement with those of ELISA 2XR. All the test agreements were supported by 
kappa value (Table 1). 
 
Diagnostic performance of assays on suspect false positive samples 
When four diagnostic methods applied to the SFP samples (group 2), none of them was 
successful in giving all negative results. Frequency of negative result given by each method 
is summarized in Table 2. Individually, MIA and WIB performed best in reducing the rate of 
SFP, although both of them still had 12 positive samples out of the 68 SFP samples. ELISA 
X3 still detected 15 samples as positive although it was still better than bELISA which gave 
24 positives in total. Among the 68 SFP samples, 3 were identified as positive by all assays. 
The majority (86.7%=10.3%+ 27.9%+ 48.5%) of the tested SFP samples were identified 
as PRRS negative when multiple assays were applied (Table 3). The best outcome for 
reducing the SFP rate were obtained when combining results of WIB and ELISA X3 (73.5%) 
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if more than one method had been randomly combined. Combination of MIA and WIB 
(72.1%) or MIA and ELISA X3 (70.6%) showed comparable outcome. The bELISA, 
however, performed poorly in reducing the SFP rate when compared with other three 
methods individually or in combination 
 
Statistical analysis of test performance 
Cochran’s Q Test and McNemar’s Test were used to compare the effectiveness of MIA, 
WIB, ELISA X3 and bELISA when diagnosing cases of SFP, validation positive and 
validation negative samples. The results of analyses are summarized in Table 4.   
The Cochran’s Q Test showed that all four tests were equally effective when testing true 
positive and true negative samples (i.e., group 1 and 4), but they have different effectiveness 
when testing cases of SFP (group 2) or inconclusive (group 3). For the cases of SFP, 
McNemar’s Test showed that any two methods among MIA, WIB and ELISA X3 were 
equally effective (p>0.05). In contrast, bELISA was determined not to have the same 
effectiveness (p<0.05) as MIA or WIB but appeared to have the same effectiveness as ELISA 
X3.  
On group 3 samples with S/P ratios between 0.2 and 0.4 (i.e., inconclusive potentially 
false negative or marginally true negative), McNemar’s Tests showed that all pairwise 
comparisons among the 4 assays had the same effectiveness, except comparing WIB and 
ELISA X3. WIB determined 30 of the 31 samples negative (97.4% specificity), but ELISA 
X3 determined only 20 of the 31 samples negative which gave a specificity of 81.6%. 
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Discussion 
Monitoring the serologic status of swine herds for PRRSV is critical for disease 
prevention and control. Although there is no true “gold standard” for PRRSV serodiagnosis, 
ELISA has been most commonly used in veterinary diagnostic laboratories because the assay 
is relatively easy to perform and can provide high throughput while other serologic tests can 
be expensive and/or time-consuming 20. Once a commercial ELISA kit (IDEXX) became a 
widely accepted tool in the diagnostic community, the occurrence of unexpected false 
positive results at a higher rate than expected has become a great concern to the swine 
industry with respect to disease control and prevention. Several competitive or bELISA have 
been applied to minimize the occurrence of SPF results 7,12,35. However, lower-than-desired 
levels of specificity were obtained, leading to the desire for a more thoroughly validated 
serologic assay with high level of accuracy.  
Products of baculovirus expressing system are generally considered to be immunogenic; 
therefore, they can be used to establish various immunoassays. In this study, recombinant 
baculoviruses containing the gene encoding for the putative N proteins of type 1 or 2 PRRSV 
were constructed and used to express the proteins in insect cells. The N protein was chosen 
since it is known to be antigenically conserved among PRRS viruses. Baculovirus-expressed 
fusion N proteins were shown to be antigenically similar to the native N protein as they were 
detected by porcine anti-PRRSV sera in WIB. Using the recombinant N protein, WIB and 
MIA were able to clear more than 80% of SFP sera as negative, demonstrating their 
usefulness as good confirmatory test. A disadvantage of WIB was that the assay could not 
detect antibody specific for the N protein until 14 dpi, whereas MIA was able to detect the 
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antibody at 7 dpi.  
Microsphere immunoassay has shown many promising characteristics as future serologic 
assay but has not been applied to PRRSV diagnostics. This study demonstrated that the 
diagnostic sensitivity and specificity of the recombinant PRRSV N protein-based MIA were 
excellent in a small aliquot of serum (≤10μl). In comparison to IFA test which has been 
commonly used as confirmatory test for SFP samples in the veterinary diagnostic community, 
MIA is more convenient and can provide rapid turnaround, especially when screening a large 
numbers of sera. The MIA also provides a quantitative test result, whereas the IFA generally 
produces qualitative result unless endpoint titration is carried out. The significant advantage 
of MIA in comparison to WIB is its capacity for multiplexing with additional target 
antigen(s), therefore, the specificity of the test can be enhanced while maintaining the same 
level of sensitivity. 
The epitope-based bELISA had the same sensitivity (95%) and specificity (92.4%) as 
MIA. However, the assay produced most false positive samples when it was conducted on the 
SFP samples. The fluctuation in test performance was also observed among different ELISA 
2XR plates which were used in bELISA, which may account for poor performance of the 
bELISA as compared to the other three assays. The IDEXX PRRS ELISA X3 kit was able to 
reduce the SFP rate as claimed by the manufacturer. Interestingly, the kit produced more 
positive results when it was run on samples tested negative by ELISA 2XR, particularly ones 
with S/P ratio between 0.2 and 0.4. This could be due to the increased sensitivity of the assay 
or test specificity has been compromised. The comparative assessment in this study indicated 
that the bELISA and ELISA X3 may have lower specificity than ELISA 2XR. Therefore, 
these 2 ELISAs are not recommended as confirmatory testing. The assays, particularly 
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ELISA X3 would be rather more suitable for rapid screening tests which can substantially 
reduce a number of SFP reactors. 
Although all the assays employed in the study displayed a relatively good diagnostic 
sensitivity and diagnostic specificity and were capable of reducing the SFP sample numbers, 
none of individual assay could reduce the rate by 100%. The maximum reduction of the SFP 
rate by individual testing was 82.4%. On the other hand, when more than one assay were 
combined, the frequency of SPF samples was further reduced by as high as 73.5%, implying 
that more than one test may be needed for confirmation of SFP samples. The study results 
suggest that WIB and ELISA X3 are the best pair with best performance for confirmatory 
testing. Considering that the ELISA X3 may have lower-than-desired specificity, a testing 
algorithm suggested for confirmation is then that samples with SFP result in the ELISA 2XR 
should be tested first by ELISA X3 and then by WIB. 
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FIGURE LEGEND 
Figure 1. Photographs of agarose gels showing the PCR products of recombinant virus 
bac-6xHis-ORF7NA or bac-6xHis-ORF7EU (A) and nested PCR products of type 
1 or type 2 PRRSV ORF7 (B). Lanes 1-3 and 4-6 in the panel A are PCR product 
of bac-6xHis-ORF7NA and bac-6xHis-ORF7EU, respectively, with M13 primers. 
Lanes 1-3 and 4-6 in the panel B are PCR products of type 1 and 2 PRRSV ORF7, 
respectively which were amplified with gene specific primers from the 
corresponding PCR products shown in the panel A as template. 
 
Figure 2. Western immunoblotting confirmation of expression of the recombinant PRRSV 
nucleocapsid proteins in sf9 insect cells transfected with bacmid DNA 
bac-6xHis-ORF7EU and bac-6xHis-ORF7EU using anti-PRRSV polyclonal 
antiserum raised against VR2332. WT represents crude antigen prepared from 
wild-type baculovirus-infected Sf9 cells. Molecular weight (MW) markers are 
given in kDa to the left of the figure. 
 
Figure 3. Western immunoblot analysis of bac-6xHis-ORF7EU and bac-6xHis-ORF7NA 
recombinant protein before and after purification. Lanes 1 and 2 on each 
nitrocellulose membrane is unpurified and purified proteins recognized by 
PRRSV-specific antiserum, respectively. 
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Figure 4. Western immunoblot analysis of the reactivity of purified recombinant type 1 PRRSV 
nucleocapsid (bac-6xHis-ORF7EU) protein (A) and recombinant type 2 PRRSV nucleocapsid 
(bac-6xHis-ORF7NA) protein (B) with PRRSV nucleocapsid protein-specific monoclonal 
antibodies (MAbs) SDOW 17, SR 30, VO17, JP24 and EP147, porcine anti-LV serum, and 
negative control serum. MAbs VO17, JP24 and EP147 are specific only for type 2 PRRS 
viruses whereas MAbs SDOW17 and SR30 detect both type 1 and type 2 PRRS viruses. 
Molecular weight (MW) markers are given in kDa to the left of the figure. 
 
Figure 5. Readout of microsphere immunoassay using recombinant PRRSV nucleocapsid 
protein on serum samples collected from experimental pigs with known PRRSV 
infection status. The median fluorescence intensity (MFI) of each serum is 
indicated by red bar. X1 to X16 represent 16 known negative sera whereas X17 
through X32 represent 16 known positive sera. 
 
Figure 6. Comparison of test performance over time on serum sequentially bled from 11 
pigs experimentally infected with PRRSV. The X axis represents days post 
infection; Y axis represents number of positive/negative results. Each method is 
represented by a different color bar as indicated on the figure. 
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Table 1. Diagnostic performance of selected serologic assays in comparison to ELISA 2XR 
on swine sera selected from submissions to the Iowa State University Diagnostic Laboratory 
which had more than 10 serum samples per case. The status of each sample was first 
determined by ELISA 2XR and IFA/PCR along with herd history.  
Category ELISA 2XR MIA WIB ELISA X3 bELISA
TP 60 57 58 60 57 
TN 92 85 90 78 85 
FP 0 7 2 14 7 
FN 0 3 2 0 3 
Sensitivity(%) N/A 95.0 96.7 100.0 95.0 
Specificity(%) N/A 92.4 97.8 84.8 92.4 
Test Agreement (%)  93.4 97.4 90.8 93.4 
κ Value  0.864 0.945 0.815 0.864 
TP: True Positive 
TN: True Negative 
FP: False Positive 
FN: False Negative 
Sensitivity%= 100*TP/(TP+FN) 
Specificity%= 100*TN/(TN+FP) 
Test agreement=100*number of samples with agreed test results/number of total samples 
tested 
κ value: 0.81-1.00 almost perfect agreement 
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Table 2. Frequency of negative results given by each assay on suspect false positive samples 
which were determined by ESLIA 2XR and IFA/PCR along with herd history. 
 
Method Frequency % reduction 
MIA 56/68 82.4 
WIB 56/68 82.4 
ELISA X3 53/68 77.9 
bELISA 44/68 64.7 
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Table 3. Frequency of negative results in suspected false positive samples based on different 
combinations of results from all four assays evaluated. Methods 1, 2, 3 and 4 are recombinant 
PRRSV nucleocapsid protein-based microsphere immunoassay, Western immunoblotting 
using recombinant PRRSV nucleocapsid protein, ELISA X3 (IDEXX) and epitope-based 
blocking ELISA utilizing ELISA 2XR (IDEXX), respectively. 
 
PRRS Negative Samples, based on Frequency % 
General Combinations   
None of the Methods 3/68 4.4 
Any 1 Method 6/68 8.8 
Any 2 Methods 7/68 10.3 
Any 3 Methods 19/68 27.9 
Any 4 Methods 33/68 48.5 
Specific Combinations   
Methods 1 and 2 49/68 72.1 
Methods 1 and 3 48/68 70.6 
Methods 1 and 4 39/68 57.4 
Methods 2 and 3 50/68 73.5 
Methods 2 and 4 38/68 55.9 
Methods 3 and 4 38/68 55.9 
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Table 4. Cochran's Q test and McNemar’s Test results. P value<0.05 is indicative of 
significant difference (i.e., not equal between assays). 
 
 Group 
Positive 
(s/p≥0.4) 
False 
Positive 
Inconclusive 
(s/p<0.2) 
Negative 
(0.2≤s/p<0.4) 
Overall Difference 
(Cochran’s Q) 
N/A 0.0103* 0.6659 0.0061 
MIA vs. WIB 1.0000 1.0000 1.0000 0.1250 
MIA vs. ELISA X3 0.25 0.5811 0.6250 0.0625 
MIA vs. bELISA 1.0000 0.0169 1.0000 1.0000 
WIB vs. ELISA X3 0.5 0.5078 0.6250 0.0020 
WIB vs. bELISA 1.0000 0.0227 1.0000 0.2188 
ELISA X3 vs. bELISA 0.25 0.0784 1.0000 0.1460 
*P value for comparison of proportions between diagnostic tests. 
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Appendix 
 
Group 1 samples test results by four diagnostic methods. 
Sample # MIA WIB ELISA X3 bELISA 
1 pos neg pos pos 
2 pos pos pos pos 
3 pos pos pos pos 
4 pos pos pos pos 
5 pos pos pos pos 
6 pos pos pos pos 
7 pos pos pos pos 
8 pos pos pos pos 
9 pos pos pos pos 
10 pos pos pos pos 
11 pos pos pos pos 
12 pos pos pos pos 
13 pos pos pos pos 
14 pos neg pos neg 
15 pos pos pos pos 
16 pos pos pos pos 
17 pos pos pos pos 
18 pos pos pos pos 
19 pos pos pos pos 
20 pos pos pos pos 
21 pos pos pos pos 
22 neg pos pos pos 
23 pos pos pos pos 
24 pos pos pos pos 
25 neg pos pos pos 
26 neg pos pos pos 
27 pos pos pos pos 
28 pos pos pos pos 
29 pos pos pos pos 
30 pos pos pos pos 
31 pos pos pos pos 
32 pos pos pos neg 
33 pos pos pos pos 
34 pos pos pos pos 
35 pos pos pos pos 
36 pos pos pos pos 
37 pos pos pos pos 
38 pos pos pos neg 
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Group 1 samples test results by four diagnostic methods continued. 
39 pos pos pos pos 
40 pos pos pos pos 
41 pos pos pos pos 
42 pos pos pos pos 
43 pos pos pos pos 
44 pos pos pos pos 
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Group 2 samples test results by four diagnostic methods. 
Sample 
# MIA WIB ELISA X3 bELISA 
Sample 
# MIA WIB ELISA X3 bELISA 
1 neg neg neg neg 35 neg neg neg pos 
2 neg neg neg neg 36 neg pos neg neg 
3 neg neg neg neg 37 pos neg neg pos 
4 neg neg neg neg 38 neg neg neg neg 
5 neg neg neg neg 39 neg neg neg neg 
6 neg neg neg neg 40 neg pos neg pos 
7 neg neg neg neg 41 neg neg neg neg 
8 neg neg neg neg 42 neg neg neg pos 
9 neg neg neg pos 43 neg neg neg pos 
10 neg neg neg neg 44 neg neg neg pos 
11 neg neg neg pos 45 neg neg neg pos 
12 neg neg neg neg 46 neg neg neg pos 
13 neg neg neg neg 47 neg neg neg pos 
14 pos pos pos neg 48 neg neg neg pos 
15 neg neg neg pos 49 neg neg neg neg 
16 neg neg neg neg 50 neg neg neg neg 
17 neg neg neg neg 51 neg neg neg neg 
18 pos neg pos pos 52 pos neg pos pos 
19 neg neg neg neg 53 pos neg neg pos 
20 pos neg neg neg 54 pos pos pos pos 
21 neg neg neg neg 55 neg neg neg neg 
22 neg pos pos neg 56 neg neg pos pos 
23 neg pos pos pos 57 neg neg neg neg 
24 neg pos neg neg 58 neg neg neg neg 
25 neg neg neg pos 59 neg neg neg neg 
26 neg neg neg neg 60 neg pos pos pos 
27 neg neg neg neg 61 pos pos pos pos 
28 pos pos pos pos 62 neg neg neg neg 
29 neg pos pos neg 63 neg neg neg neg 
30 pos pos pos neg 64 neg neg neg neg 
31 neg neg pos neg 65 pos neg neg neg 
32 neg neg pos neg 66 neg neg neg neg 
33 pos neg neg neg 67 neg neg neg neg 
34 neg neg pos pos 68 neg neg neg neg 
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Group 3 samples test results by four diagnostic methods. 
Sample # MIA WIB ELISA X3 bELISA 
1 neg neg neg neg 
2 neg neg neg neg 
3 neg neg neg pos 
4 neg neg pos neg 
5 neg neg neg neg 
6 neg neg neg neg 
7 neg neg neg neg 
8 neg neg neg neg 
9 neg neg neg neg 
10 neg neg neg neg 
11 pos neg pos neg 
12 pos neg pos neg 
13 neg neg neg neg 
14 neg neg pos pos 
15 pos neg pos pos 
16 neg neg neg neg 
17 neg pos pos neg 
18 neg neg neg neg 
19 neg neg pos neg 
20 neg neg pos neg 
21 neg neg neg neg 
22 neg neg neg neg 
23 neg neg neg neg 
24 pos neg pos neg 
25 pos neg pos neg 
26 pos neg pos neg 
27 neg neg neg neg 
28 neg neg neg neg 
29 neg neg neg pos 
30 neg neg neg neg 
31 neg neg neg pos 
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Group 4 samples test results by four diagnostic methods. 
Sample # MIA WIB ELISA X3 bELISA 
1 neg neg neg neg 
2 neg neg neg neg 
3 neg neg neg neg 
4 neg neg neg neg 
5 neg neg neg neg 
6 neg neg neg neg 
7 neg neg neg neg 
8 neg neg neg neg 
9 neg neg neg neg 
10 neg neg neg neg 
11 neg neg neg neg 
12 neg neg neg neg 
13 neg neg neg neg 
14 neg neg neg neg 
15 neg neg neg neg 
16 neg pos neg neg 
17 neg neg neg neg 
18 neg neg neg neg 
19 neg neg neg neg 
20 neg neg neg neg 
21 neg neg neg neg 
22 neg neg neg neg 
23 neg neg neg neg 
24 neg neg neg neg 
25 neg neg neg neg 
26 neg neg neg neg 
27 neg neg neg neg 
28 neg neg neg neg 
29 neg neg pos neg 
30 neg neg neg neg 
31 neg neg neg neg 
32 neg neg neg neg 
33 neg neg neg neg 
34 neg neg pos neg 
35 neg neg neg neg 
36 neg neg neg neg 
37 neg neg neg neg 
38 neg neg neg neg 
39 pos neg neg neg 
40 neg neg pos neg 
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Group 4 samples test results by four diagnostic methods continued. 
41 neg neg neg pos 
42 neg neg neg neg 
43 neg neg neg neg 
44 neg neg neg neg 
45 neg neg neg pos 
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CHAPTER 3: GENERAL CONCLUSION 
Serology diagnostic tools aid in PRRS control strategies 
Samples for serodiagnostics can be easily obtained from live pigs to determine the PRRS 
status of the animals. Several tests detect the pig’s immune response to PRRSV and ELISA 
has been most commonly used for that purpose. Few, if any, serological tests reach 100% 
accuracy, no exception for PRRS diagnostics. All serological tests are expected to have some 
degree of error, and even widely used commercial IDEXX ELISA 2XR kit has is known to 
have the false-positive rate of 0.5-1%. In populations expected to be PRRS-negative, even 
1% false positive rate can be a serious concern for PRRSV control and eradication. 
Follow-up tests commonly including PCR, VI, IFA and SVN are ‘must’ to confirm or 
disprove the unexpected test results. The inherent limitations of each of these tests, however, 
made them less desirable as follow-ups. In our study, three in-house developed serology 
methods (Western immunoblotting, microsphere immunoassay, epitope-based blocking 
ELISA) as well as newly released commercial ELISA X3 kits were evaluated for their 
performance as possible confirmatory tests. 
Diagnostic sensitivity and specificity of all four methods were good and can be 
acceptable for use in diagnosis. As compared to the current IDEXX PRRS ELISA (2XR), all 
of them were able to reduce the number of suspected false positive samples substantially, 
ranging from 64.7% to 82.4%. Combining results of two different methods also reduced the 
SFP results by as high as 73.5%. Although this is not as good as individual method results, it 
does provide higher level of confidence when dealing a SFP sample. Although different 
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combination of tests can be chosen by laboratories and veterinarians depending upon their 
concerns and testing infrastructure, a recommendation for confirmatory testing based on 
observations of the current study would be a combination of WIB and ELISA 3X. 
Obviously the more assays we apply to samples, the higher confidence we will get to 
confirm the true status of the samples. In reality, however, not all of the diagnostic methods 
can be employed by laboratories due to various practical constraints (e.g., infrastructure, 
expertise and personnel, etc.). For producers, the cost is an important factor to consider when 
diagnostic investigation or disease surveillance is necessary. Serology is not an exception to 
that even though it is much cheaper than other diagnostics such as PCR, virus isolation or 
tissue immunoassays. Our study suggested that a recombinant nucleocapsid protein-based 
WIB or MIA can be a rapid and reliable alternative to traditional IDEXX ELISAs when 
evaluating sera with suspected false positive results. Their high sensitivity and specificity 
also makes these tests useful in determining PRRSV infection status which can aid in the 
management of PRRS outbreaks. In case that proper instrumentation or skills to develop 
WIB or MIA is lacking, bELISA format of the ELISA 2XR may be a viable option since no 
special equipment is required for this assay and the original commercial ELISA kit can still 
be utilized without too many changes. If a single assay must be chosen among the assays 
evaluated, the new IDEXX PRRS ELISA X3 has promising future as it showed much better 
performance than the 2XR kit in reducing SFP rate while maintaining the level of sensitivity 
similar to that of the 2XR and high throughput capability. All these advantages make the X3 
kit an excellent screening test with higher accuracy. 
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Accurate data interpretation 
For all PRRS diagnostics, it is important to understand benefits and limitations of each 
assay to insure proper use and interpretation. Taking ELISA as a good example and 
comparing to other serology assays, it provides excellent quantitative information on PRRSV 
infection status of a herd and also provides a standardized universal platform for diagnostic 
testing whose results can be interchangeable between laboratories. However, care should be 
taken not to over-interpret the S/P ratio beyond determination of herd status for PRRSV 
infection. One of key elements that should be taken into consideration when interpreting 
result is the timing of the sampling in relation to time of exposure to the virus (i.e., disease 
kinetics). In our study, ELISA, bELISA, WIB and IFA test could not detect PRRSV-specific 
antibodies until 14 dpi whereas MIA detected the antibodies as early as 7 dpi.Another 
important element is the sample pool/size used for test evaluation. Because there is no 
universally accepted method to determine the true status of field samples, care should be 
taken in selecting samples, otherwise biased results can be obtained, leading to the incorrect 
conclusion. Thus, diagnostic tools are only as good as their valid and reliable use and the 
careful interpretation of their results. 
 
Future work 
Our present study demonstrated four assays can greatly reduce the SFP rate when 
subjected with unexpected positive samples. However, diagnostic sensitivity and specificity 
were not extremely high as hoped for. Although field samples used in this study were 
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carefully selected from submissions to ISU-VDL according to their ELISA and IFA or PCR 
results as well as the knowledge based on the farm history, it would have been impossible for 
us to know their absolutely true status for PRRSV. Therefore, biased results might be 
generated and affected the performance of the assays employed in the study. This suggests 
that the methods used may still have a room for improvement. In order to prove that, more 
samples with known infection status should be tested by all the assays in the near future to 
improve our understanding on their performance and feasibility in PRRSV diagnosis. 
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